research use only
Cat.No.S4041
|
In vitro |
Water : 41 mg/mL
DMSO
: 4 mg/mL
(11.55 mM)
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 346.2 | Formula | C14H8N2O6.2Na |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 6054-98-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)[O-])C(=O)O)C(=O)O)[O-].[Na+].[Na+] | ||
| In vitro |
Olsalazine displays multiple effects on intestinal electrolyte. In vitro application of Olsalazine (< 2.89 mM) increases the secretion of both sodium and chloride ions and decreases chloride ion absorption in rat and rabbit ileal mucosa. Concentration of Olsalazine < 11.5 mM also dose-dependently decreases net sodium and, to a greater degree, chloride absorption in the isolated rat colon. Potassium secretion is also increases but only at a high Olsalazine concentration (11.5 mM). Olsalazine also inhibits absorption of glucose and lactose in isolated rat jejunum.
Olsalazine is potent inhibitors of human intestinal macrophages chemotaxis to LTB4 with IC50 of 0.39 mM. Olsalazine (0.4 mM) inhibits the superoxide radical production generated by phorbol myristate acetate (PMA)-activated neutrophils or by xanthine-xanthine oxidase reaction by reduction of 31% and 73%, respectively. Other suggested possible mechanisms by which Olsalazine-derived mesalazine might ameliorate colonic mucosa/inflammation are inhibition of platelet activating factor, inhibition of cytokine production in human mononuclear cells, suppression of colonic fatty acid oxidation, inhibition of endothelial cell proliferation by folic acid antagonism, inhibition of leukotriene synthesis from arachidonic acid via inhibition of lipoxygenase, modulation of the prostaglandin profile by an effect on prostaglandin 15-hydroxydehydrogenase, and interference with leukocyte function.
|
|---|---|
| In vivo |
Olsalazine is developed as a way of delivering mesalazine to the colon, since very little of parent molecule is absorbed from the gastrointestinal tract following oral administration. In the colon, azoreductase bacteria cleave the azo bond, releasing 2 molecules of mesalazine which has demonstrated therapeutic effect in inflammatory bowel diseases. Olsalazine (50mg/kg/day) significantly prolongs the survival of nu/nu CD-1 mice with experimental colitis induced by dextran sulphate sodium.
Olsalazine inhibits tumor growth in a rodent model of colorectal cancer. In 1,2-dimethylhydrazine-treated rats, Olsalazine (25 mg/kg/day) decreases number and volume of tumors by 58.17% and 62.67%, respectively. Administration of Olsalazine induces a 1.7-fold times increase in the number of apoptotic cells, companied with a reduction of 42.4% in cell proliferation rate.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.